Vascular endothelial cell growth inhibitor, VEGI-192a

• US 7,498,407 B2
• Filed: 11/12/2002
• Issued: 03/03/2009
• Est. Priority Date: 11/09/2001
• Status: Expired due to Fees

• Current Assignee: Georgetown University
• Original Assignee: Georgetown University
• Inventors: Pan, Hongguang, Li, Luyuan
• Primary Examiner(s): Canella; Karen A
• Assistant Examiner(s): Reddig; Peter J
• Application Number:
  US10/294,249
• Publication Number:
  US 20030170242A1
• Time in Patent Office: 2,303 Days
• Field of Search: 530/350
• US Class Current: 530/350
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 14/70575 NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154 NGF C07K14/48, TNF C07K14/525
• CPC Class Codes: C07K 2319/00 Fusion polypeptide

Abstract

This invention discloses two new VEGI isoforms named VEGI-_192a and VEGI-_192b consisting of 192 amino acid residues. These isoforms show endothelial cell-specific expression and share a C-terminal 151-residues segment with the previously described VEGI-₁₇₄ and VEGI-₂₅₁. Methods of using these isoforms of VEGI in diagnosing, screening agonist and antagonist of the isoforms, and treating various angiogenesis-related diseases are also disclosed.

Claims

1. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:

4.

2. A fusion protein comprising the polypeptide of claim 1 fused to another polypeptide.

3. The fusion protein of claim 2, wherein the polypeptide is fused to an amino acid sequence that facilitates purification of the polypeptide.

4. The fusion protein of claim 2, wherein the polypeptide is fused to an amino acid sequence encoding an epitope selected from the group consisting Myc, HA derived influenza virus hemagglutinin, and His-6.

6. The isolated polypeptide of claim 1, wherein the isolated polypeptide consists of the amino acid sequence of SEQ ID NO:

4.

7. A composition comprising the polypeptide of claim 1.

8. A composition comprising the polypeptide of claim 6.

9. A composition comprising the polypeptide of claim 6, and further comprising a pharmaceutically acceptable excipient.

5. A polypeptide produced by a method comprising expressing a polynucleotide comprising a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:

4 in E. coli.

10. A composition comprising the polypeptide of claim 5.